This past year saw immunotherapy advances in a number of cancer types, expanding its benefits to more patients, both young and old. Breakthroughs in treatments and biomarker analysis are enabling doctors to tailor their approaches to individual patients more than ever before, although much work remains to be done.
In this webinar for patients and caregivers, Kunle Odunsi, M.D., Ph.D., of Roswell Park Comprehensive Cancer Center, discusses these important milestones as well as what might lie ahead for the field in 2021—and what it means for patients. During this webinar, Dr. Odunsi will touch on a range of immunotherapy-related topics, including:
- new applications of checkpoint inhibitor immunotherapies
- combinations of immunotherapies and other treatments
- using biomarkers to pair patients with immunotherapies
- promising cell therapy strategies, and more!
Dr. Kunle Odunsi is the deputy director of the Roswell Park Comprehensive Cancer Center, in addition to holding the Robert, Anne & Lew Wallace Endowed Chair in Cancer Immunotherapy and serving as the executive director of the Center for Immunotherapy there. He is also the Chair and the M. Steven Piver Professor of Roswell Park’s Department of Gynecologic Oncology, an associate director of the CRI Scientific Advisory Council, and in 2018 was inducted into the National Academy of Medicine.
The “Cancer Immunotherapy and You” webinar series is produced by the Cancer Research Institute and is hosted by our senior science writer, Arthur N. Brodsky, Ph.D. The 2021 series is made possible with generous support from Bristol Myers Squibb.
Browse our Cancer Immunotherapy and You Webinar Series playlist on YouTube or visit the Webinars page on our website to see other webinars in this series.